Treatments

A quick summaries of each product is provided with links to learn more. No deep dives — just all the bleeding options, in one place.

Von Willebrand Disease

Intravenous

Products Available Soon

Estimated Release Date in the U.S.: First Half of 2027

Bleeding Disorder: Hemophilia A

Product: Frehemgo (denecimig), Formerly Mim8

Dosing Frequency: Every 1, 2 or 4 weeks

Administration: Subcutaneous Injection

Delivery System: Prefilled Pen

Pediatric Approval: Expected Pediatric Approval

Approved in Other Countries: Yes, Saudi Arabia. Pending in China and Europe

Inhibitor Indication: Indicated for both inhibitors and non-inhibitor patients

Derived From Human Blood: No

Recombinant Factor: No

Functionality: Bridges activated factor IX and factor X

Manufacturer: Novo Nordisk

Learn more

Intravenous

Von Willebrand Disease

Product: Alphanate

Average Adult Half-life: Factor VIII 17.9 hours
VWD 7.7 hours

Pediatric Approval Status: Pediatric approved for use prior to surgery only. VWD type 3 excluded

Administration: Intravenous

First Approved in the U.S.: 1978

Derived From Human Blood: No

Derived From: Human Plasma

Manufacturer: GRIFOLS

Manufacturer Copay Assistance: For previously enrolled patients only

Product Assistance Program: Yes

Learn more
Product: Wilate

Average Adult Half-life: 10.6 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2009

Derived From Human Blood: No

Derived From: Human Plasma

Manufacturer: Octapharma

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Humate-P

Average Adult Half-life: Factor VIII 12.2 hours and VWD 11 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 1986

Derived From Human Blood: Yes

Derived From: Human Plasma

Manufacturer: CSL Behring

Manufacturer Copay Assistance: $12,000

Product Assistance Program: Yes

Learn more
Product: VonVendi

Average Adult Half-life: VWD 19.1-22.6 hours dependent upon dosing

Administration: Intravenous

Pediatric Approval Status: Pediatric approved for on demand treatment and surgery only

First Approved in the U.S.: 2015

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: Takeda

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more

Intravenous

Hemophilia A

Intravenous

Product: Xyntha

Average Adult Half-life: 11.2 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2008

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: Pfizer

Manufacturer Copay Assistance: $12,000

Product Assistance Program: Yes

Learn more
Product: Nuwiq

Average Adult Half-life: 17.1 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2015

Derived From Human Blood: No

Derived From: Human Embryonic Kidney (HEK) cell line

Manufacturer: Octapharma

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Alphanate

Average Adult Half-life: Factor VIII 17.9 hours VWD 7.7 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 1978

Derived From Human Blood: Yes

Derived From: Human Plasma

Manufacturer: Grifols

Manufacturer Copay Assistance: For previously enrolled patients only

Product Assistance Program: Yes

Learn more
Product: Eloctate

Average Adult Half-life: 19.7 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2014

Derived From Human Blood: No

Derived From: Human Embryonic Kidney (HEK) cell line

Manufacturer: Sanofi

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Koate-DVI

Average Adult Half-life: 16.1 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 1974

Derived From Human Blood: Yes

Derived From: Human Plasma

Manufacturer: Kedrion

Manufacturer Copay Assistance: $15,000

Product Assistance Program: No

Learn more
Product: Jivi

Average Adult Half-life: 17.9 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2018

Derived From Human Blood: No

Derived From: Baby Hamster Kidney (BHK) cell line

Manufacturer: Bayer

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: ADVATE

Average Adult Half-life: 12 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2003

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cell line

Manufacturer: Takeda

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Esperoct

Average Adult Half-life: 21.7 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2019

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: Novo Nordisk

Manufacturer Copay Assistance: $15,000

Product Assistance Program: Yes

Learn more
Product: Wilate

Average Adult Half-life: 10.6 hours

Administration: Intravenous

Pediatric Approval Status: Not studied in children for hemophilia A

First Approved in the U.S.: 2009

Derived From Human Blood: Yes

Derived From: Human Plasma

Manufacturer: Octapharma

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Afstyla

Average Adult Half-life: 14.2 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2016

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: CSL Behring

Manufacturer Copay Assistance: $12,000

Product Assistance Program: Yes

Learn more
Product: Altuviiio

Average Adult Half-life: 48.2 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2023

Derived From Human Blood: No

Derived From: Human Embryonic Kidney (HEK) cell line

Manufacturer: Sanofi

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Kovaltry

Average Adult Half-life: 14.2 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.:2016

Derived From Human Blood: No

Derived From: Baby Hamster Kidney (BHK) cell line

Manufacturer: Bayer

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Novoeight

Average Adult Half-life: 12.4 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2013

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: Novo Nordisk

Manufacturer Copay Assistance: $15,000

Product Assistance Program: Yes

Learn more
Product: ADYNOVATE

Average Adult Half-life: 14.7 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2015

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: Takeda

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Humate-P

Average Adult Half-life: 12.2 hours

Administration: Intravenous

Pediatric Approval Status: Not studied in children for hemophilia A

First Approved in the U.S.: 1986

Derived From Human Blood: Yes

Derived From: Human Plasma

Manufacturer: CSL Behring

Manufacturer Copay Assistance: $12,000

Product Assistance Program: Yes

Learn more

Hemophilia A

Intravenous

Sub Q

Alhemo

Dosing Frequency: Daily

Administration: Subcutaneous Injection

Pediatric Approval Status: Approved for children aged 12 years and older

First Approved in the U.S.: 2024

Inhibitor Indication: Indicated for both inhibitors and non-inhibitor patients

Derived From Human Blood: No

Type: Monoclonal Antibody

Manufacturer: Novo Nordisk

Manufacturer Copay Assistance: $15,000

Manufacturer Product Assistance Program: Yes

Learn more
Hemlibra

Dosing Frequency: Every 1, 2 or 4 weeks

Administration: Subcutaneous Injection

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2017

Inhibitor Indication: Indicated for both inhibitors and non-inhibitor patients

Derived From Human Blood: No

Type: Monoclonal Antibody

Manufacturer: Genentech

Manufacturer Copay Assistance: $15,000

Manufacturer Product Assistance Program: Yes

Learn more
Hympavzi

Dosing Frequency: Every 7 days

Administration: Subcutaneous Injection

Pediatric Approval Status: Approved for children aged 6 years and older

First Approved in the U.S.: 2024

Inhibitor Indication: Indicated for both inhibitors and non-inhibitor patients

Derived From Human Blood: No

Type: Monoclonal Antibody

Manufacturer: Pfizer

Manufacturer Copay Assistance: $15,000

Manufacturer Product Assistance Program: Yes

Learn more
Qfitlia

Dosing Frequency: Every 1 or 2 months

Administration: Subcutaneous Injection

Pediatric Approval Status: Approved for children aged 12 years and older

First Approved in the U.S.: 2025

Inhibitor Indication: Indicated for both inhibitors and non-inhibitor patients

Derived From Human Blood: No

Type: mRNA

Manufacturer: Sanofi

Manufacturer Copay Assistance: $20,000

Manufacturer Product Assistance Program: Yes

Learn more

Hemophilia A & B with Inhibitors

Intravenous

Product: FEIBA

Average Adult Half-life: "The pharmacokinetic properties of FEIBA have not been formally studied in humans." Every 6-12 hours dosing

Administration: Intravenous

Pediatric Approval Status: All the Bleeding Options is waiting on a pharmacist's confirmation regarding status.

First Approved in the U.S.: 1986

Derived From Human Blood: Yes

Derived From: Human Plasma

Manufacturer: Takeda

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Novoseven RT

Average Adult Half-life: 2-3 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 1999

Derived From Human Blood: No

Derived From: Baby Hamster Kidney (BHK) cell line

Manufacturer: Novo Nordisk

Manufacturer Copay Assistance: $15,000

Product Assistance Program: Yes

Learn more
Product: SevenFACT

Average Adult Half-life: 1.6 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children aged 12 years and older

First Approved in the U.S.: 2020

Derived From Human Blood: No

Derived From: Genetically Engineered Rabbit's Milk

Manufacturer: HEMA Biologics

Manufacturer Copay Assistance: $12,000

Product Assistance Program: Yes

Learn more

Intravenous

Hemophilia B

Product: Rixubis

Average Adult Half-life: 26.7 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2013

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: Takeda

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Alprolix

Average Adult Half-life: 86 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2014

Derived From Human Blood: No

Derived From: Human Embryonic Kidney (HEK) cell line

Manufacturer: Sanofi

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: AlphaNine SD

Average Adult Half-life: 21 hours

Administration: Intravenous

Pediatric Approval Status: Not studied in children

First Approved in the U.S.: 1996

Derived From Human Blood: Yes

Derived From: Human plasma

Manufacturer: Grifols

Manufacturer Copay Assistance: No annual limits

Product Assistance Program: Yes

Learn more
Product: Idelvion

Average Adult Half-life: 104 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2016

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: CSL Behring

Manufacturer Copay Assistance: $20,000

Product Assistance Program: Yes

Learn more
Product: Profilnine

Average Adult Half-life: 24.7 hours

Administration: Intravenous

Pediatric Approval Status: Not studied in children

First Approved in the U.S.: 1986

Derived From Human Blood: Yes

Derived From: Human plasma

Manufacturer: Grifols

Manufacturer Copay Assistance: No

Product Assistance Program: No

Learn more
Product: Ixinity

Average Adult Half-life: 24 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2015

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: Medexus

Manufacturer Copay Assistance: $12,000

Product Assistance Program: Yes

Learn more
Product: BeneFIX

Average Adult Half-life: 22.4 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 1997

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: Pfizer

Manufacturer Copay Assistance: $12,000

Product Assistance Program: Yes

Learn more
Product: Rebinyn

Average Adult Half-life: 115 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2017

Derived From Human Blood: No

Derived From: Chinese Hamster Ovary (CHO) cells

Manufacturer: Novo Nordisk

Manufacturer Copay Assistance: $15,000

Product Assistance Program: Yes

Learn more

Sub Q

Hympavzi

Dosing Frequency: Every 7 days

Administration: Subcutaneous Injection

Pediatric Approval Status: Approved for children aged 6 years and older

First Approve in the U.S.: 2024

Inhibitor Indication: Indicated for non-inhibitor patients only

Derived From Human Blood: No

Type: Monoclonal Antibody

Manufacturer: Pfizer

Manufacturer Copay Assistance: $15,000

Manufacturer Product Assistance Program: Yes

Learn more
Qfitlia

Dosing Frequency: Every 1 or 2 months

Administration: Subcutaneous Injection

Pediatric Approval Status: Approved for children aged 12 years and older

First Approve in the U.S.: 2025

Inhibitor Indication: Indicated for both inhibitors and non-inhibitor patients

Derived From Human Blood: No

Type: mRNA

Manufacturer: Sanofi

Manufacturer Copay Assistance: $20,000

Manufacturer Product Assistance Program: Yes

Learn more
Alhemo

Dosing Frequency: Daily

Administration: Subcutaneous Injection

Pediatric Approval Status: Approved for children aged 12 years and older

First Approve in the U.S.: 2024

Inhibitor Indication: Indicated for both inhibitors and non-inhibitor patients

Derived From Human Blood: No

Type: Monoclonal Antibody

Manufacturer: Novo Nordisk

Manufacturer Copay Assistance: $15,000

Manufacturer Product Assistance Program: Yes

Learn more

Gene Therapy

Product: Hemgenix

Average Factor IX at 2 Years: 37%

Administration: One time in-hospital infusion

Pediatric Approval Status: Not studied in children

Pre-existing antibodies to adeno-associated virus serotype 5 accessibility: Acceptable. Patients that test positive for adeno-associated virus serotype 5 antibodies may still be able to receive Hemgenix.

Derived From Human Blood: No

Gene Therapy Type: Adeno-associated virus vector-based (AAV5)

Manufacturer: CSL Behring

First Approved in the U.S.: 2022

Manufacturer Financial Assistance Program: Yes

Learn more

Intravenous

Factor X Deficiency

Product: Coagadex

Average Adult Half-life: 30.3 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2015

Derived From Human Blood: Yes

Derived From: Human Plasma

Manufacturer: Kedrion

Manufacturer Copay Assistance: $15,000

Product Assistance Program: No

Learn more

Fibrin Stabilizing Factor Deficiency/Factor XIII (13) Deficiency

Intravenous

Product: Corifact

Average Adult Half-life: 7.1 days

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2011

Derived From Human Blood: Yes

Derived From: Human Plasma

Manufacturer: CSL Behring

Manufacturer Copay Assistance: No

Product Assistance Program: Yes

Learn more
Product: Tretten

Average Adult Half-life: 5.1 days

Administration: Intravenous

Pediatric Approval Status: Approved for children aged 6 years and older

First Approved in the U.S.: 2013

Derived From Human Blood: No

Derived From: Saccharomyces Cerevisiae

Manufacturer: Novo Nordisk

Manufacturer Copay Assistance: $15,000

Product Assistance Program: Yes

Learn more

Alexander’s Disease/Factor VII (7) Deficiency

Intravenous

Product: Novoseven RT

Average Adult Half-life: 2-3 hours

Administration: Intravenous

Pediatric Approval Status: All the Bleeding Options is waiting on a pharmacist's confirmation regarding status.

First Approved in the U.S.: 1999

Derived From Human Blood: No

Derived From: Baby Hamster Kidney (BHK) cell line

Manufacturer: Novo Nordisk

Manufacturer Copay Assistance: $15,000

Product Assistance Program: Yes

Learn more

Fibrinogen Deficiency/Factor I (1) Deficiency

Intravenous

Product: fibryga/Fibrinogen

Average Adult Half-life: 75.9 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2017

Derived From Human Blood: Yes

Derived From: Human Plasma

Manufacturer: Octapharma

Manufacturer Copay Assistance: $2,500

Product Assistance Program: Yes

Learn more
Product: RiaSTAP

Average Adult Half-life: 82.3 hours

Administration: Intravenous

Pediatric Approval Status: Approved for children of all ages

First Approved in the U.S.: 2009

Derived From Human Blood: Yes

Derived From: Human Plasma

Manufacturer: CSL Behring

Manufacturer Copay Assistance: No

Product Assistance Program: Yes

Learn more

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Intravenous

Product: Cablivi

Average Adult Half-life: "The half-life of Cablivi is concentration and target-level dependent."

Administration: Intravenous and Subcutaneous

Pediatric Approval Status: Approved for children aged 12 years and older

First Approved in the U.S.: 2019

Derived From Human Blood: No

Derived From: Escherichia Coli

Manufacturer: Sanofi

Manufacturer Copay Assistance: $25,000

Product Assistance Program: Yes

Learn more

Multiple Diagnosis Medications

Oral, Nasal Spray, and Intravenous

Brand name: Amicar

Generic Name: Aminocaproic Acid

Common Dosing Frequency: Every 8 hours

Administration: Oral, Nasal Spray, Intravenous

Pediatric Approval Status: Status has not been established

First Approved in the U.S.: 1964

Derived From Human Blood: No

Active Ingredient: Aminocaprioc Acid

Manufacturer: Amicar is and has been manufactured by numerous different companies.

Manufacturer Copay Assistance: No

Product Assistance Program: No

Learn more
Brand name: Lysteda
Generic Name: Tranexamic Acid
Common Dosing Frequency: 1-3 Times Daily
Administration: Oral, Nasal Spray, Intravenous
Pediatric Approval Status: Status has not been established
First Approved in the U.S.: 1986
Derived From Human Blood: No
Active Ingredient: Tranexamic Acid
Manufacturer: Ferring
Manufacturer Copay Assistance: No
Product Assistance Program: No
Learn more
Brand name: DDAVP

Generic Name: Desmopressin

Common Dosing Frequency: 1-3 Times Daily

Administration: Oral, Nasal Spray, Intravenous

Pediatric Approval Status: Approved for children aged 4 years and older

First Approved in the U.S.: 1978

Derived From Human Blood: No

Active Ingredient: Desmopressin Acetate

Manufacturer: Ferring

Manufacturer Copay Assistance: No

Product Assistance Program: No

Learn more

Treatments

Products Available Soon

Intravenous

Von Willebrand Disease

Intravenous

Hemophilia A

Sub Q

Alhemo

Hemlibra

Hympavzi

Qfitlia

Sub Q

Hympavzi

Qfitlia

Alhemo

Gene Therapy

Fibrinogen Deficiency/Factor I (1) Deficiency